The role of asymmetric dimethylarginine and arginine in the failing heart and its vasculature

European Journal of Heart Failure

Volumn 12, Issue 12, 2010, Pages 1274-1281

  Visser, Marlieke ^a,b   Paulus, Walter J ^a   Vermeulen, Mechteld A R ^a   Richir, Milan C ^c   Davids, Mariska ^a   Wisselink, Willem ^a   De Mol, Bas A J M ^b   Van Leeuwen, Paul A M ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c Location Alkmaar   (Netherlands)

Author keywords

Arginine; Asymmetric dimethylarginine; Coronary vasculature; Failing heart; Nutritional therapy

Indexed keywords

ARGININE; CITRULLINE; DIMETHYLARGININASE; GLUTAMINE; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE;

AMINO ACID METABOLISM; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DIET SUPPLEMENTATION; DIET THERAPY; ENZYME INHIBITION; HEART BLOOD VESSEL; HEART DISEASE; HEART FAILURE; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HUMAN; NONHUMAN; PRIORITY JOURNAL; REOXYGENATION; REVIEW;

AMIDOHYDROLASES; ARGININE; CITRULLINE; CORONARY VESSELS; GLUTAMIC ACID; HEART FAILURE; HUMANS; NITRIC OXIDE; REACTIVE OXYGEN SPECIES;

EID: 78649657831     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1093/eurjhf/hfq158     Document Type: Review

References (44)

1. Umar S, Van der Laarse A. Nitric oxide and nitric oxide synthase isoforms in the normal, hypertrophic, and failing heart. Mol Cell Biochem 2010;333:191-201.
2. Siroen MP, Teerlink T, Nijveldt RJ, Prins HA, Richir MC, Van Leeuwen PA. The clinical significance of asymmetric dimethylarginine. Annu Rev Nutr 2006;26: 203-228.
3. Bode-Boger SM, Scalera F, Ignarro LJ. The L-arginine paradox: importance of the L-arginine/asymmetrical dimethylarginine ratio. Pharmacol Ther 2007;114: 295-306.
4. Nijveldt RJ, Teerlink T, Van der Hoven B, Siroen MP, Kuik DJ, Rauwerda JA, Van Leeuwen PA. Asymmetrical dimethylarginine (ADMA) in critically ill patients: high plasma ADMA concentration is an independent risk factor of ICU mortality. Clin Nutr 2003;22:23-30.
5. Boger RH, SulliVan LM, Schwedhelm E, Wang TJ, Maas R, Benjamin EJ, Schulze F, Xanthakis V, Benndorf RA, Vasan RS. Plasma asymmetric dimethylarginine and incidence of cardiovascular disease and death in the community. Circulation 2009;119:1592-1600.
6. Richir MC, Van Lambalgen AA, Teerlink T, Wisselink W, Bloemena E, Prins HA, de Vries TP, Van Leeuwen PA. Low arginine/asymmetric dimethylarginine ratio deteriorates systemic hemodynamics and organ blood flow in a rat model. Crit Care Med 2009;37:2010-2017.
7. Dzavik V, Cotter G, Reynolds HR, Alexander JH, Ramanathan K, Stebbins AL, Hathaway D, Farkouh ME, Ohman EM, Baran DA, Prondzinsky R, Panza JA, Cantor WJ, Vered Z, Buller CE, Kleiman NS, Webb JG, Holmes DR, Parrillo JE, Hazen SL, Gross SS, Harrington RA, Hochman JS. Effect of nitric oxide synthase inhibition on haemodynamics and outcome of patients with persistent cardiogenic shock complicating acute myocardial infarction: a phase II dose-ranging study. Eur Heart J 2007;28:1109-1116.
8. Cotter G, Kaluski E, Milo O, Blatt A, Salah A, Hendler A, Krakover R, Golick A, Vered Z. LINCS: L-NAME (a NO synthase inhibitor) in the treatment of refractory cardiogenic shock: a prospective randomized study. Eur Heart J 2003;24: 1287-1295.
9. Lopez A, Lorente JA, Steingrub J, Bakker J, McLuckie A, Willatts S, Brockway M, Anzueto A, Holzapfel L, Breen D, Silverman MS, Takala J, Donaldson J, Arneson C, Grove G, Grossman S, Grover R. Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. Crit Care Med 2004;32: 21-30.
10. Avontuur JA, Bruining HA, Ince C. Inhibition of nitric oxide synthesis causes myo-cardial ischemia in endotoxemic rats. Circ Res 1995;76:418-425.
11. Sydow K, Munzel T. ADMA and oxidative stress. Atheroscler Suppl 2003;4:41-51.
12. Takimoto E, Kass DA. Role of oxidative stress in cardiac hypertrophy and remodeling. Hypertension 2007;49:241-248.
13. Chen Y, Li Y, Zhang P, Traverse JH, Hou M, Xu X, Kimoto M, Bache RJ. Dimethy-larginine dimethylaminohydrolase and endothelial dysfunction in failing hearts. Am J Physiol Heart Circ Physiol 2005;289:H2212-H2219.
14. Chin-Dusting JP, Willems L, Kaye DM. L-arginine transporters in cardiovascular disease: a novel therapeutic target. Pharmacol Ther 2007;116:428-436.
15. Mendes Ribeiro AC, Brunini TM, Ellory JC, Mann GE. Abnormalities in L-arginine transport and nitric oxide biosynthesis in chronic renal and heart failure. Cardio-vasc Res 2001;49:697-712.
16. Wang J, Sim AS, Wang XL, Salonikas C, Naidoo D, Wilcken DE. Relations between plasma asymmetric dimethylarginine (ADMA) and risk factors for coronary disease. Atherosclerosis 2006;184:383-388.
17. Korandji C, Zeller M, Guilland JC, Vergely C, Sicard P, Duvillard L, Gambert P, Moreau D, Cottin Y, Rochette L. Asymmetric dimethylarginine (ADMA) and hyperhomocysteinemia in patients with acute myocardial infarction. Clin Biochem 2007;40:66-72.
18. Achan V, Broadhead M, Malaki M, Whitley G, Leiper J, MacAllister R, Vallance P. Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscler Thromb Vasc Biol 2003;23:1455-1459.
19. Liu H, Qu X, Liang Z, Chen W, Xia W, Song Y. Variance of DDAH/PRMT/ADMA pathway in atrial fibrillation dogs. Biochem Biophys Res Commun 2008;377: 884-888.
20. Gray GA, Patrizio M, Sherry L, Miller AA, Malaki M, Wallace AF, Leiper JM, Vallance P. Immunolocalisation and activity of DDAH I and II in the heart and modification post-myocardial infarction. Acta Histochem 2010;112:413-423.
21. Stuhlinger MC, Conci E, Haubner BJ, Stocker EM, Schwaighofer J, Cooke JP, Tsao PS, Pachinger O, Metzler B. Asymmetric dimethyl L-arginine (ADMA) is a critical regulator of myocardial reperfusion injury. Cardiovasc Res 2007;75: 417-425.
22. Smith CL, Birdsey GM, Anthony S, Arrigoni FI, Leiper JM, Vallance P. Dimethylar-ginine dimethylaminohydrolase activity modulates ADMA levels, VEGF expression, and cell phenotype. Biochem Biophys Res Commun 2003;308:984-989.
23. Garbin U, Pasini AF, Stranieri C, Manfro S, Boccioletti V, Cominacini L. Nebivolol reduces asymmetric dimethylarginine in endothelial cells by increasing dimethylarginine dimethylaminohydrolase 2 (DDAH2) expression and activity. Pharmacol Res 2007;56:515-521.
24. Achan V, Tran CT, Arrigoni F, Whitley GS, Leiper JM, Vallance P. All-trans-Retinoic acid increases nitric oxide synthesis by endothelial cells: a role for the induction of dimethylarginine dimethylaminohydrolase. Circ Res 2002;90:764-769.
25. Eid HM, Lyberg T, Arnesen H, Seljeflot I. Insulin and adiponectin inhibit the TNFalpha-induced ADMA accumulation in human endothelial cells: the role of DDAH. Atherosclerosis 2007;194:e1-e8.
26. Morris SM Jr. Recent adVances in arginine metabolism: roles and regulation of the arginases. Br J Pharmacol 2009;157:922-930.
27. Prins HA, Houdijk AP, Van Lambalgen AA, Teerlink T, Meijer S, Thijs LG, Van Leeuwen PA. Paradoxical changes in organ blood flow after arginase infusion in the non-stressed rat. Shock 1998;9:422-427.
28. Prins HA, Houdijk AP, Wiezer MJ, Teerlink T, Van Lambalgen AA, Thijs LG, Van Leeuwen PA. The effect of mild endotoxemia during low arginine plasma levels on organ blood flow in rats. Crit Care Med 2000;28:1991-1997.
29. Zhang JG, Galinanes M. Role of the L-arginine/nitric oxide pathway in ischaemic/ reoxygenation injury of the human myocardium. Clin Sci (Lond) 2000;99:497-504.
30. Shiono N, Rao V, Weisel RD, Kawasaki M, Li RK, Mickle DA, Fedak PW, Tumiati LC, Ko L, Verma S. L-arginine protects human heart cells from low-volume anoxia and reoxygenation. Am J Physiol Heart Circ Physiol 2002;282: H805-H815.
31. Boger RH. The pharmacodynamics of L-arginine. J Nutr 2007;137:1650S- 1655S.
32. Giugliano D, Marfella R, Verrazzo G, Acampora R, Coppola L, Cozzolino D, D'Onofrio F. The vascular effects of L-Arginine in humans. The role of endogenous insulin. J Clin Invest 1997;99:433-438.
33. Paulus WJ, Kastner S, Vanderheyden M, Shah AM, Drexler H. Myocardial contractile effects of L-arginine in the human allograft. J Am Coll Cardiol 1997;29: 1332-1338.
34. Brooks WW, Conrad CH, Robinson KG, Colucci WS, Bing OH. L-arginine fails to prevent ventricular remodeling and heart failure in the spontaneously hypertensive rat. Am J Hypertens 2009;22:228-234.
35. Fontanive P, Saponati G, Iurato A, Volterrani C, Boni A, Piccioni L, Dini FL. Effects of L-arginine on the Minnesota Living with Heart Failure Questionnaire quality-of-life score in patients with chronic systolic heart failure. Med Sci Monit 2009;15:CR606-CR611.
36. Schulman SP, Becker LC, Kass DA, Champion HC, Terrin ML, Forman S, Ernst KV, Kelemen MD, Townsend SN, Capriotti A, Hare JM, Gerstenblith G. L-arginine therapy in acute myocardial infarction: the Vascular Interaction With Age in Myo-cardial Infarction (VINTAGE MI) randomized clinical trial. JAMA 2006;295:58-64.
37. Luiking YC, Poeze M, Dejong CH, Ramsay G, Deutz NE. Sepsis: an arginine deficiency state? Crit Care Med 2004;32:2135-2145.
38. Romero MJ, Platt DH, Caldwell RB, Caldwell RW. Therapeutic use of citrulline in cardiovascular disease. Cardiovasc Drug Rev 2006;24:275-290.
39. Schwedhelm E, Maas R, Freese R, Jung D, Lukacs Z, Jambrecina A, Spickler W, Schulze F, Boger RH. Pharmacokinetic and pharmacodynamic properties of oral L-citrulline and L-arginine: impact on nitric oxide metabolism. Br J Clin Pharmacol 2008;65:51-59.
40. Smith HA, Canter JA, Christian KG, Drinkwater DC, Scholl FG, Christman BW, Rice GD, Barr FE, Summar ML. Nitric oxide precursors and congenital heart surgery: a randomized controlled trial of oral citrulline. J Thorac Cardiovasc Surg 2006;132:58-65.
41. Ligthart-Melis GC, Van de Poll MC, Boelens PG, Dejong CH, Deutz NE, Van Leeuwen PA. Glutamine is an important precursor for de novo synthesis of argi-nine in humans. Am J Clin Nutr 2008;87:1282-1289.
42. Houdijk AP, Van Leeuwen PA, Boermeester MA, Van LT, Teerlink T, Flinkerbusch EL, Sauerwein HP, Wesdorp RI. Glutamine-enriched enteral diet increases splanchnic blood flow in the rat. Am J Physiol 1994;267:G1035-G1040.
43. Wu G, Meininger CJ. Regulation of nitric oxide synthesis by dietary factors. Annu Rev Nutr 2002;22:61-86. (Pubitemid 35221454)
44. Vermeulen MA, Van de Poll MC, Ligthart-Melis GC, Dejong CH, Van den Tol MP, Boelens PG, Van Leeuwen PA. Specific amino acids in the critically ill patient- exogenous glutamine/arginine: a common denominator? Crit Care Med 2007;35: S568-S576.